Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with a software based tachycardia reversion pacemaker.

A W Nathan, J E Creamer, D W Davies

    Pacing and Clinical Electrophysiology : PACE
    |November 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adverse effects of amiodarone at low dose: plus ça change.

    Journal of the American College of Cardiology·1997
    Same author

    Atrial premature beats preceding episodes of paroxysmal atrial fibrillation: factorial analysis of a prediction system.

    Pacing and clinical electrophysiology : PACE·1997
    Same author

    Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy.

    Japanese circulation journal·1997
    Same author

    Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.

    Circulation·1997
    Same author

    Chlamydia pneumoniae and coronary heart disease.

    BMJ (Clinical research ed.)·1997
    Same author

    Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.

    Lancet (London, England)·1997

    A new antitachycardia pacemaker (Intermedics Intertach 262-12) effectively controls pathological tachycardia in patients resistant to drug therapy. This advanced device offers improved detection and termination, significantly reducing arrhythmia burden.

    Area of Science:

    • Cardiology
    • Biomedical Engineering

    Background:

    • Current antitachycardia pacemakers have limitations in detecting and distinguishing pathological tachycardias.
    • Existing devices also present challenges with available termination modes for arrhythmias.

    Purpose of the Study:

    • To evaluate the efficacy of a novel antitachycardia pacemaker, the Intermedics Intertach 262-12.
    • To assess the device's ability to overcome limitations of current pacemaker technology in managing pathological tachycardias.

    Main Methods:

    • The Intermedics Intertach 262-12 device was implanted in nine patients.
    • All patients had a history of failed drug treatment for their arrhythmias.

    Main Results:

    • All nine patients achieved complete control of their arrhythmias post-implantation.

    Related Experiment Videos

  • Only one patient required continued drug therapy after the implantation of the new device.

    • Conclusions:

    • The Intermedics Intertach 262-12 demonstrates significant success in managing pathological tachycardias.
    • This new pacemaker offers a viable alternative for patients with drug-refractory arrhythmias, improving arrhythmia control.